You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》瑞银首予欧康维视生物-B(01477.HK)「买入」评级 目标价34.2元
阿思达克 04-01 09:38
瑞银发表的研究报告,首予欧康维视生物(01477.HK)「买入」评级,认为眼科药市场快速发展加上在创新眼科药物上竞争温和,相信公司主要强势在於其多元、创新的产品,可覆盖各种眼疾,加上其商用化能力或可降本增效。该行估计公司今年将在内地推创新药YUTIQ,认为现时其估值低於同业,市场忽略了公司OT-401加快获批的影响,同时亦未反映其产品线带来的潜在增长。

该行指出2019年内地眼科药物市场规模为28亿美元,相当於美国市场的五分之一,料到2030年将增长至169亿美元,意味年复合增长达17.8%,相信增长主要是受惠於创新药推出,满足到医疗需求,不过现时内地仅数家眼科药生产商是专注於创新药,而欧康维视生物覆盖的眼疾则是同业中最广。

该行指出公司商业化团队有69人,覆盖267家医院,去年4至12月收入达1,310万元人民币,按季增长达215.5%,核心产品YUTIQ估计加快至今年获批,予公司目标价34.2元,评级「买入」。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account